A compound according to formula I wherein R1 is independently selected from H, fluoro, chloro and bromo; G is selected from G1 to G3, wherein R2 is independently selected from H and C1-2 alkyl, Y is selected from S and NR3, (het)Ar is a monocyclic aromatic ring; said ring being substituted with a maximum of "n" independently selected substituent(s) R4 at any substitutable ring atom, wherein "n" represents an integer number; The integer number "n" is 0 (zero) to 2 (two); R3 is selected from H, C1-5 alkyl, C2-5 fluoroalkyl, C1-3 alkyleneOC0-5 alkyl, C0-3 alkyleneNHC0-3 alkyl, C0-3 alkyleneN(C1-5 alkyl)2, in which the C1-5 alkyl may be the same or different, C1-5 alkyl, N(C0-5 alkyl)2, in which the C0-5 alkyl may be the same or different, and OC1-5 alkyl; Two R2 or R2 and R3, if present, may optionally be connected to each other by a bond replacing a hydrogen atom in each substituent to form part of a 5-membered or a 6-membered ring, or R2 or R3 may optionally be connected to the carbon- or nitrogen-atom onto which the other R2 or R3 is attached in case the other R2 or R3 is hydrogen by a bond replacing a hydrogen atom in each substituent to form part of a 5-membered or a 6-membered ring; R4 is independently selected from C1-5 alkyl, C1-5 fluoroalkyl, halo, OH, NH2, C0-C3 alkylene phenyl, C0-C3 alkylene heteroaryl, C0-1 alkylene cyano, C0-3 alkyleneOC0-5 alkyl, C0-3 alkyleneNHC0-3 alkyl, C0-3 alkyleneN(C1-5 alkyl)2, in which the C1-5 alkyl may be the same or different, N(C4-5 alkylene), N -morpholino, CO2H, C0-3 alkyleneC OC0-5 alkyl, C0-3 alkyleneOC C0-5 alkyl, C0-3 alkyleneN(C0-3 alkyl)C C0-3 alkyl, C0-3 alkyleneC NHC0-3 alkyl, C0-3 alkyleneC N(C1-5 alkyl)2, in which the CI-5 alkyl may be the same or different, C0-3 alkyleneC N(C4-5 alkylene) and NH2; as a free base, an acid in its non-charged protonated form or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof and as a pure stereoisomer, a racemic-, diastereomeric- or scalemic mixture. R1 is independently selected from H, fluoro, chloro and bromo; G is selected from G1 to G3, wherein R2 is independently selected from H and C1-2 alkyl, Y is selected from S and NR3, (het)Ar is a monocyclic aromatic ring; said ring being substituted with a maximum of "n" independently selected substituent(s) R4 at any substitutable ring atom, wherein "n" represents an integer number; The integer number "n" is 0 (zero) to 2 (two); R3 is selected from H, C1-5 alkyl, C2-5 fluoroalkyl, C1-3 alkyleneOC0-5 alkyl, C0-3 alkyleneNHC0-3 alkyl, C0-3 alkyleneN(C1-5 alkyl)2, in which the C1-5 alkyl may be the same or different, C1-5 alkyl, N(C0-5 alkyl)2, in which the C0-5 alkyl may be the same or different, and OC1-5 alkyl; Two R2 or R2 and R3, if present, may optionally be connected to each other by a bond replacing a hydrogen atom in each substituent to form part of a 5-membered or a 6-membered ring, or R2 or R3 may optionally be connected to the carbon- or nitrogen-atom onto which the other R2 or R3 is attached in case the other R2 or R3 is hydrogen by a bond replacing a hydrogen atom in each substituent to form part of a 5-membered or a 6-membered ring; R4 is independently selected from C1-5 alkyl, C1-5 fluoroalkyl, halo, OH, NH2, C0-C3 alkylene phenyl, C0-C3 alkylene heteroaryl, C0-1 alkylene cyano, C0-3 alkyleneOC0-5 alkyl, C0-3 alkyleneNHC0-3 alkyl, C0-3 alkyleneN(C1-5 alkyl)2, in which the C1-5 alkyl may be the same or different, N(C4-5 alkylene), N -morpholino, CO2H, C0-3 alkyleneC OC0-5 alkyl, C0-3 alkyleneOC C0-5 alkyl, C0-3 alkyleneN(C0-3 alkyl)C C0-3 alkyl, C0-3 alkyleneC NHC0-3 alkyl, C0-3 alkyleneC N(C1-5 alkyl)2, in which the CI-5 alkyl may be the same or different, C0-3 alkyleneC N(C4-5 alkylene) and NH2; as a free base, an acid in its non-charged protonated form or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof and as a pure stereoisomer, a racemic-, diastereomeric- or scalemic mixture.